HESTER BIOSCIENCES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,814 INR | +1.55% |
|
+4.00% | +24.30% |
| 10/05 | Transcript : Hester Biosciences Limited, Q4 2024 Earnings Call, May 10, 2024 | |
| 10/05 | Hester Biosciences' Consolidated Net Profit Rises in Fiscal Q4; Shares Jump 4% | MT |
Presentation Operator MessageOperator (Operator)Good day, and welcome to Hester Biosciences Q2...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Hester Biosciences Limited is an India-based animal healthcare company. The Company is engaged in providing vaccines, health products and diagnostic laboratory services. The Company operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Poultry Healthcare products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and Thermostable ND. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet and Hestaliv.
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q1 2025 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +24.30% | 18Cr | |
| -13.83% | 7.76TCr | |
| +12.68% | 829.73Cr | |
| +24.00% | 367.35Cr | |
| +0.14% | 327.05Cr | |
| +15.20% | 166.58Cr | |
| -4.46% | 158.72Cr | |
| +3.32% | 134.85Cr | |
| -22.01% | 130.42Cr | |
| -12.12% | 114.92Cr |
- Stock Market
- Equities
- HESTERBIO Stock
- News Hester Biosciences Limited
- Transcript : Hester Biosciences Limited, Q2 2022 Earnings Call, Oct 28, 2021
